SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Nov 6, 2017
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Nov. 6, 2017 · CIK: 0001390478 · Accession: 0001193125-17-333517
AI Filing Summary & Sentiment
Reasoning
Letter
GALENA BIOPHARMA, INC.
2000 Crown Canyon Place, Suite 380
San Ramon, CA 94583
November 6, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: Galena Biopharma, Inc.
Registration Statement on Form S-4, as may be amended from time to time
File No. 333- 220592
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced Registration Statement on Form S-4 (the “Registration Statement”) be accelerated so that the Registration Statement will become effective on November 6, 2017 at 4:30 p.m. Eastern time, or as soon thereafter as practicable.
In connection with the Registration Statement, the Company hereby acknowledges that:
•
should the U.S. Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission, or the Staff acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, please do not hesitate to contact Keith Pisani of Paul Hastings LLP at (212) 318-6053. The Company respectfully requests that it be notified of the effectiveness of the Registration Statement by a telephone call to Keith Pisani and that such effectiveness also be confirmed in writing.
U.S. Securities and Exchange Commission
November 6, 2017
Page
Very truly yours,
GALENA BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP GALENA BIOPHARMA, INC. 2000 Crown Canyon Place, Suite 380 San Ramon, CA 94583 November 6, 2017 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Galena Biopharma, Inc. Registration Statement on Form S-4, as may be amended from time to time File No. 333- 220592 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced Registration Statement on Form S-4 (the “Registration Statement”) be accelerated so that the Registration Statement will become effective on November 6, 2017 at 4:30 p.m. Eastern time, or as soon thereafter as practicable. In connection with the Registration Statement, the Company hereby acknowledges that: • should the U.S. Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; • the action of the Commission, or the Staff acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and • the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions, please do not hesitate to contact Keith Pisani of Paul Hastings LLP at (212) 318-6053. The Company respectfully requests that it be notified of the effectiveness of the Registration Statement by a telephone call to Keith Pisani and that such effectiveness also be confirmed in writing. U.S. Securities and Exchange Commission November 6, 2017 Page 2 Very truly yours, GALENA BIOPHARMA, INC. By: /s/ Stephen F. Ghiglieri Stephen F. Ghiglieri Interim Chief Executive Officer & Chief Financial Officer cc: Keith D. Pisani, Esq. Paul Hastings LLP